How to Preserve Native Conformation During Immunogen Preparation

To preserve native conformation during immunogen preparation, I start with an antigen design that reflects the target’s biological state, minimize conditions that can unfold or aggregate the protein, and verify structural integrity with fit-for-purpose assays before immunization. The right approach depends on whether the target is soluble, membrane-bound, multimeric, glycosylated, or dependent on a ligand or binding partner. For nanobody discovery, I also check that the antigen remains accessible in the form relevant to the intended veterinary application. No single buffer or handling protocol preserves every antigen equally well.

Click here to get more.

Why native conformation matters

Many antibodies recognize three-dimensional epitopes formed by amino acids that are distant in the primary sequence. If preparation exposes or destroys those surfaces, screening may favor binders to denatured regions rather than the target’s biologically relevant form. This can reduce the likelihood that selected nanobodies recognize the target in a cell, tissue, or functional assay.

Preservation is especially important for veterinary targets whose activity or accessibility depends on species-specific sequence, post-translational modifications, oligomerization, or membrane context. A soluble recombinant fragment may be convenient to produce, but it may not display all the epitopes found on the native protein. I therefore treat antigen format as an experimental design decision, not just a procurement detail.

A practical workflow for preserving conformation

1. Define the biological state to reproduce

Before selecting an antigen, clarify what the discovery campaign needs to recognize: an extracellular domain, full-length receptor, assembled complex, pathogen surface protein, or ligand-bound state. Confirm the relevant species and, where possible, the sequence or isoform used in the intended assay. For veterinary work, this helps avoid discovering binders that recognize a related species but not the target animal.

Then identify structural features that could be lost during production. These may include disulfide bonds, glycosylation, lipid association, oligomeric partners, or a required cofactor. If the native target is membrane-associated, consider whether a detergent-solubilized protein, nanodisc, liposome, or cell-based presentation is more appropriate than an isolated soluble domain.

2. Choose an antigen format that suits the target

Purified recombinant protein can be practical when the target is stable and its relevant epitopes remain intact outside the cell. A construct should include the region needed for recognition while avoiding unnecessary truncations that remove structural support. Tags can aid purification, but their location and size should be considered because they may affect folding, accessibility, or assay interpretation.

For difficult membrane proteins or complexes, native-like particles or cells may better preserve context. These formats can introduce their own challenges, including batch variability, background binding, and more demanding quality controls. When a target depends on a binding partner or ligand, compare antigen alone with the assembled state if the intended nanobody must recognize the complex.

3. Keep handling conditions controlled

Follow the antigen supplier’s validated storage and handling instructions whenever available. During routine chilled handling, keeping samples at 2–8 °C can reduce exposure to warm conditions, but this range is not a guarantee of stability for every protein. Limit time outside the recommended storage condition and avoid vigorous mixing if the antigen is prone to aggregation or foaming.

Repeated freezing and thawing can stress some proteins, so divide material into single-use aliquots when the sample volume and formulation allow. As a development check, compare antigen quality after 0, 1, and 3 freeze-thaw cycles rather than assuming all targets respond the same way. A short hold study, such as assessing a sample after 24 hours at 2–8 °C, can also help determine whether the planned preparation and transfer workflow is practical; it should not replace target-specific stability testing.

You will get efficient and thoughtful service from NBbiolab.

4. Match buffer and adjuvant to the antigen

Buffer composition can influence solubility, aggregation, and binding activity. Salt, pH, reducing agents, detergents, preservatives, and stabilizing excipients should be assessed for compatibility with the target and downstream immunization plan. A formulation suitable for purification or analytical testing may not be suitable for injection, so confirm requirements with the responsible immunization team and applicable protocols.

Adjuvants are intended to support an immune response, but mixing can alter antigen behavior or obscure epitopes depending on the antigen and formulation. I recommend checking antigen recovery and integrity after mixing, where feasible, and documenting the order of addition and preparation time. Avoid assuming that a visually uniform mixture proves the protein remains correctly folded.

5. Verify the antigen before use

Use more than one type of evidence when the project risk warrants it. Analytical methods such as size-exclusion chromatography can indicate whether the preparation contains aggregates or multiple size populations, while electrophoresis can help assess apparent purity and degradation. These methods do not, by themselves, prove that a conformational epitope remains intact.

Pair structural or aggregation checks with a functional or binding-based assay where a suitable reagent is available. For example, binding by a known conformational antibody, ligand, or native binding partner can provide useful evidence that a relevant surface remains accessible. For cell-surface targets, confirmation in a cell-based assay may be more informative than testing purified protein alone.

Key decision points for B2B buyers

Ask a supplier to distinguish confirmed product specifications from project-specific expectations. Useful documentation may include construct details, expression system, purification method, storage formulation, and available analytical results. If a supplier cannot confirm a property, treat it as an open question to resolve before committing the antigen to a costly discovery campaign.

Common mistakes that compromise native structure

• Choosing a construct only for convenience: A short fragment may express well yet omit stabilizing regions or the intended epitope.
• Using purity as a substitute for folding evidence: A clean gel does not establish native conformation or biological activity.
• Ignoring the final assay: An antigen can perform well in a plate-based assay but poorly represent a cell-surface target.
• Changing formulation without review: Buffer exchange or adjuvant mixing may affect solubility, binding, or stability.
• Failing to document handling: Without storage and freeze-thaw records, it is difficult to interpret inconsistent results.

How NBbiolab can support immunogen preparation planning

At NBbiolab, we support B2B discussions around immunogen preparation for nanobody discovery, including the fit between target biology, antigen format, and downstream screening needs. For veterinary projects, we recommend sharing the target species, sequence or construct information, intended assay, and any known requirements for native partners or post-translational modifications. This allows the preparation plan to address biological relevance as well as material handling.

Before starting, buyers can ask which preparation options are feasible, what quality checks can be provided, and which properties require separate validation. We encourage project teams to agree on acceptance criteria in advance, especially for membrane proteins, complexes, and targets with limited stability. This makes it easier to compare suppliers on technical fit rather than on purity or price alone.

Key takeaways and next steps

Preserving native conformation begins with selecting an antigen that represents the target state needed for discovery, then maintaining compatible handling and formulation conditions. I recommend verifying both sample quality and relevant binding or function, because appearance and purity do not establish that conformational epitopes are intact. For challenging veterinary targets, the appropriate solution may require a native-like presentation rather than a conventional soluble protein.

To move forward, define the target species and intended application, request construct and handling details, and discuss suitable quality evidence with your supplier before immunization begins. NBbiolab can review your project requirements and discuss immunogen preparation options for nanobody discovery. Contact our team with your target information and assay goals to determine the most appropriate next step.